5-Lipoxygenase Polyclonal Antibody

5-Lipoxygenase (5-LO) is an enzyme encoded by ALOX5 in humans that is involved in leukotriene biosynthesis. It is comprised of an N-terminal regulatory domain and a C-terminal catalytic domain and is primarily expressed in leukocytes. Increases in intracellular calcium levels or cellular stress induce translocation of 5-LO from the cytosol or nucleoplasm, depending on the cell type and 5-LO phosphorylation status, to the nuclear envelope, where it interacts with 5-LO-activating protein (FLAP), which transfers arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) to 5-LO. 5-LO catalyzes the conversion of arachidonic acid to 5(S)-HpETE and then to leukotriene A₄ (LTA₄). Other substrates of 5-LO include 5,8,11,14,17-eicosapentaenoic acid, 5,8,11-eicosatrienoic acid, 5,8-eicosadienoic acid, 12-HpETE, and 15-HpETE. Alox5 knockout mice are protected against arthritis and pulmonary inflammation. Knockout of Alox5 also protects apolipoprotein E-deficient hyperlipidemic mice from high-fat diet-induced hepatic injury and inflammation. Levels of 5-LO are elevated in postmortem hippocampus and cortex of patients with Alzheimer''s disease. Cayman''s 5-Lipoxygenase Polyclonal Antibody can be used for Western blot and immunohistochemistry applications. The antibody recognizes 5-LO at 78 kDa from human and porcine samples.

[1] OLOF RDMARK . 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease[J]. Biochimica et biophysica acta. Molecular and cell biology of lipids, 2015, 1851 4: Pages 331-339. DOI: 10.1016/j.bbalip.2014.08.012
[2] MARCOS MARTíNEZ-CLEMENTE  Esther T  Joan Clària. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease.[J]. Current Opinion in Clinical Nutrition and Metabolic Care, 2011: 347-353. DOI: 10.1097/mco.0b013e32834777fa
[3] RDMARK O. Arachidonate 5-lipoxygenase[J]. Journal of lipid mediators and cell signalling, 1995, 12 2: Pages 171-184. DOI: 10.1016/0929-7855(95)00017-k
[4] MARCOS MARTíNEZ-CLEMENTE. 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor α–induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice[J]. Hepatology, 2009, 51 3: 817-827. DOI: 10.1002/hep.23463
[5] OMIDREZA FIRUZI. 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer’s disease[J]. FASEB Journal, 2007, 22 4: 1169-1178. DOI: 10.1096/fj.07-9131.com
[6] ANTHONY J. APOSTOLI. Loss of PPARγ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment[J]. International Journal of Cancer, 2013, 134 5: 1055-1066. DOI: 10.1002/ijc.28432
[7] ZHIGANG XIE. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.[J]. PLoS ONE, 2011: e21583. DOI: 10.1371/journal.pone.0021583
[8] SANDRA PFISTER PHD , MBA. Mechanisms underlying increased reactivity of pulmonary arteries contralateral to a localized high-flow anastomosis[J]. Journal of Thoracic and Cardiovascular Surgery, 2011, 141 2: Pages 425-431. DOI: 10.1016/j.jtcvs.2010.07.007
[9] MICHA P WASILEWICZ. Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.[J]. International Journal of Colorectal Disease, 2010, 25 9: 1079-1085. DOI: 10.1007/s00384-010-0980-z